Ghanshyam Parmar

Prof. Ghanshyam Parmar

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in Journal of Advanced Research
Verified
Journal Article
Open access
NSNirmal V. Shah
Nirmal V. Shah
ASAvinash K. Seth
Avinash K. Seth
RBR. Balaraman
R. Balaraman
CAChintan J. Aundhia
Chintan J. Aundhia
RMRajesh A. Maheshwari
Rajesh A. Maheshwari
Ghanshyam ParmarGhanshyam Parmar
Ghanshyam Parmar
The objective of present work was to utilize potential of nanostructured lipid carriers (NLCs) for improvement in oral bioavailability of raloxifene hydrochloride (RLX). RLX loaded NLCs were prepared by solvent diffusion method using glyceryl monostearate and Capmul MCM C8 as solid lipid and liquid lipid, respectively. A full 3(2) factorial design was utilized to study the effect of two independent parameters namely solid lipid to liquid lipid ratio and concentration of stabilizer on the entrapment efficiency of prepared NLCs. The statistical evaluation confirmed pronounced improvement in entrapment efficiency when liquid lipid content in the formulation increased from 5% w/w to 15% w/w. Solid-state characterization studies (DSC and XRD) in optimized formulation NLC-8 revealed transformation of RLX from crystalline to amorphous form. Optimized formulation showed 32.50 ± 5.12 nm average particle size and -12.8 ± 3.2 mV zeta potential that impart good stability of NLCs dispersion. In vitro release study showed burst release for initial 8 h followed by sustained release up to 36 h. TEM study confirmed smooth surface discrete spherical nano sized particles. To draw final conclusion, in vivo pharmacokinetic study was carried out that showed 3.75-fold enhancements in bioavailability with optimized NLCs formulation than plain drug suspension. These results showed potential of NLCs for significant improvement in oral bioavailability of poorly soluble RLX.

1 April 2025 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
CAChintan Aundhia
Chintan Aundhia
Ghanshyam ParmarGhanshyam Parmar
Ghanshyam Parmar
CTChitrali Talele
Chitrali Talele
NSNiyati Shah
Niyati Shah
DTDipali Talele
Dipali Talele
This review explores the transformative impact of AI on drug development and delivery in pharmaceutical sciences, spanning formulation design, real-time monitoring, targeted delivery, and future prospects. The rational design of smart drug carriers, such as AI-optimized liposomes for cancer therapy, optimizes formulations for individual patient needs. AI-driven sensors, exemplified by glucose-monitoring biosensors for diabetics, enable adaptive drug administration, enhancing precision. Despite promises, challenges like biocompatibility, regulations, and ethics persist. Interdisciplinary collaboration and transparent communication are crucial for responsible AI adoption. Anticipated trends include personalized dosage optimization and intelligent nanocarriers. The review underscores AI's potential in reshaping pharmaceuticals for patient-centric care while addressing challenges for widespread adoption.

1 January 2015 in Journal of Applied Pharmaceutical Science
Verified
Journal Article
Open access
GSGirish Sailor
Girish Sailor
ASA Seth
A Seth
Ghanshyam ParmarGhanshyam Parmar
Ghanshyam Parmar
SCSachin Chauhan
Sachin Chauhan
AJAnkur Javia
Ankur Javia



31 December 2019 in Folia Medica
Verified
Journal Article
Open access
ASAshish Prasenjit Shah
Ashish Prasenjit Shah
Ghanshyam ParmarGhanshyam Parmar
Ghanshyam Parmar
GSGirish U. Sailor
Girish U. Sailor
ASAvinash K. Seth
Avinash K. Seth
Background: Aspartic protease found in plasmodium parasites such as plasmepsin I, II and IV plays an important role in the degradation of hemoglobin. The studies have shown that effective drug must be able to inhibit more than one type of plasmepsin to avoid further growth of parasites and to prevent resistance of drug. Therefore, plasmepsins are believed to be excellent drug target for malarial disease. Extract of the plant Euphorbia hirta has been proved to exert antimalarial activity. However, molecular mechanism of this activity was not described. Aim: The aim of present investigation is to identify antimalarial phytochemicals of Euphorbia hirta as plasmepsin protease inhibitors using an in silico approach. Materials and methods: Docking studies were performed on three different protein targets plasmepsin I, II, and IV using iGEMDOCK. ADME and bioactivity predictions were done using molinspiration online tool. Toxicity studies were performed using ProTox-II online tool. Results: In the docking studies seven compounds showed significant inhibitory activity with low docking score as compared to standard drug artemisinin. Six compounds showed no violations as per Lipinski rule. Bioactivity prediction states that all the compounds may act through enzyme inhibition. The results of in silico studies suggest that out of the eleven selected phytochemicals isorhamnetin and pinocembrin have more drug likeliness properties and lesser in silico toxicity with more binding affinity than artemisinin on all receptors. Conclusion: These findings indicate that isorhamnetin and pinocembrin have promising potential for development of antimalarial drug as plasmepsin inhibitors.